Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Antares Pharma, Inc. today announced the New Drug Application (NDA) for Anturol® Gel in patients with overactive bladder (OAB) was accepted for filing for review by the U.S. Food and Drug Administration (FDA). Anturol is an oxybutynin gel incorporating Antares' ATD Gel technology.

8 Apr 2011

Insurance payers extend coverage for PTNS using Uroplasty's Urgent PC Neuromodulation System for OAB

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that two private insurance payers have elected to cover posterior tibial nerve stimulation (PTNS) using its Urgent PC Neuromodulation System for the treatment of overactive bladder (OAB) and associated symptoms.

5 Apr 2011

Genetic factors can explain people's susceptibility to urinary incontinence

Much of the risk of developing incontinence before middle age is determined by our genes. Genetic factors can explain half of people's susceptibility to urinary incontinence, a study of twins at the University of Gothenburg and Karolinska Institutet reveals.

5 Apr 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization—an interventional radiology treatment for the noncancerous yet very common growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids, confirm researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

The National Association For Continence awarded Gamal Ghoniem, MD, with the Rodney Appell Continence Care Champion Award at the Society for Urodynamics and Female Urology Awards Reception on March 4, held during the 2011 SUFU Winter Meeting in Phoenix, AZ.

16 Mar 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

AMS introduces STEP toolkit to help men with ED and SUI

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced the launch of its Solutions to Educate Patients Program in Europe.

18 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.

11 Jan 2011

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

In anticipation of presenting at the JP Morgan Healthcare Conference on January 11, 2011, American Medical Systems Holdings, Inc. reported today preliminary sales of $147.0 million for the fourth quarter of 2010, a 0.7 percent increase over sales of $146.0 million in the comparable quarter of 2009.

11 Jan 2011

Pros and cons of weight loss surgery in men and women

Women who underwent gastric band surgery to lose weight reported significant improvements in urinary function and quality of life after the operation, according to research published in the January issue of the urology journal BJUI.

6 Jan 2011

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Antares Pharma, today announced the filing of a New Drug Application with the U.S. Food and Drug Administration for Anturol Gel in patients with overactive bladder.

22 Dec 2010

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.

21 Dec 2010

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Drug addiction investigators with joint appointments at Columbia University Medical Center and the New York State Psychiatric Institute along with MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Jasdaq Market of the Osaka Securities Exchange, today reported preliminary results of the company's neurological drug candidate, ibudilast (MN-166/AV411), in a Phase 1b/2a trial in opioid addicts. The study was largely funded by the National Institute on Drug Abuse (NIDA) with MediciNova supplementation.

14 Dec 2010

Emergent declares one-time cash dividend and regular dividend

Emergent Group Inc., a leading provider of mobile medical lasers and surgical equipment, today announced that the Board of Directors has declared a special, one-time cash dividend of $0.50 per share on its common stock as well as a regular dividend of $0.40 per share, for a total of $0.90 payable December 27, 2010 to shareholders of record December 17, 2010.

7 Dec 2010

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

FDA accepts Antares Pharma's Anturol NDA for filing, assigns PDUFA date

Insurance payers extend coverage for PTNS using Uroplasty's Urgent PC Neuromodulation System for OAB

Genetic factors can explain people's susceptibility to urinary incontinence

Prostatic artery embolization comparable to transurethral resection

Uterine fibroid embolization reduces fibroid-related urinary symptoms

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

Astellas announces positive results from mirabegron phase III trials against OAB

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

AMS introduces STEP toolkit to help men with ED and SUI

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Negative aspects of prostate cancer screening acceptable

FemmePharma completes FP 1097 Phase II clinical trial in women with OAB

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

Pros and cons of weight loss surgery in men and women

Antares Pharma submits NDA for Anturol Gel in patients with overactive bladder

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Preliminary results from Phase 1b/2a trial of MediciNova's ibudilast in opioid addicts announced

Emergent declares one-time cash dividend and regular dividend

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Urinary Incontinence News and Research

Latest Urinary Incontinence News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in